… ProQR Update August 2022 Announced today (August 11, 2022), ProQR will focus exclusively on the development of the … from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 …
… Building an Inclusive ProQR At ProQR we strive to create an inclusive culture where everyone … logo to incorporate the pride rainbow flag. Pride month at ProQR is an opportunity to celebrate and thank all of the …
… ProQR update and additional sepofarsen Illuminate trial analyses ProQR has announced the completion of an in-depth strategic … additional analyses of the sepofarsen *Illuminate* trial. ProQR has announced the completion of an in-depth strategic …
In June we caught up with our Lead Talent Acquisition, Silvia Catellani, to talk about ProQR, Pride, and driving an inclusive culture for present and future ProQRians.
… ProQR at TIDES to highlight our Axiomer® technology This month several ProQRians will attend the Oligonucleotide and Peptide … beyond. At this year’s TIDES Europe, Gerard Platenburg, ProQR Chief Scientific Officer, and co-founder, is presenting …
… Today marks an expansion of the ProQR and Lilly partnership In September 2021 ProQR announced a global licensing and research collaboration … originally announced in September 2021 , applied ProQR’s proprietary Axiomer® RNA editing platform to target …
… ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology LEIDEN, the Netherlands, Jan. 08, … fibrosis targets,” said Daniel A. de Boer, CEO of ProQR. “We look forward to working closely with the team at …
